- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06047236
Immune Biomarker Study for Salivary Gland Carcinoma (ImmoGlandula)
Aims of this study are analyses of tumor metabolome, tumor transcriptome and tumor proteome as well as of the immune infiltration, separated by histological entity. These data will subsequently be compared with the with the detailed immune status determined in the patient's peripheral blood and saliva using machine learning techniques, among others, to create a biomarker cluster for salivary gland tumors. These can be used in clinical routine.
In addition, the investigators would like to study a subset of patients from freshly resected tumor organoids from freshly resected tumor tissue according to already established methods in order to mechanistic investigations of prognostic parameters.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Studiensekretariat
- Phone Number: 43921 +49913185
- Email: studiensekretariat.ST@uk-erlangen.de
Study Contact Backup
- Name: Translation Radiobiology
- Phone Number: 44925 +49913185
- Email: Anna-Jasmina.Donaubauer@uk-erlangen.de
Study Locations
-
-
Bavaria
-
Erlangen, Bavaria, Germany, 91054
- Recruiting
- Universitätsklinikum Erlangen, Strahlenklinik
-
Contact:
- Marlen Haderlein, PD
- Phone Number: 33968 +49913185
- Email: marlen.haderlein@uk-erlangen.de
-
Erlangen, Bavaria, Germany, 91054
- Recruiting
- Universitätsklinikum Erlangen, HNO
-
Contact:
- Sarina Mueller, PD
- Phone Number: 43921 +49-9131-85
- Email: sarina.mueller@uk-erlangen.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Observational group
- Initial diagnosis of a primary salivary gland carcinoma in the head and neck region (no squamous cell carcinomas)
- Specimen collection from the center of the tumor when the primary tumor is sufficiently large without that the pathological assessment is impaired
Control group 1
- Initial diagnosis of a benign salivary gland tumor in the head and neck region
- Specimen collection from the center of the tumor when the primary tumor is sufficiently large without that the pathological assessment is impaired
Control group 2
- functional diseases of the nose or ear (patients with the indication for functional ear surgery and rhinoplasty)
- Specimen collection with sufficiently large resectate during a functional nose surgery
for all groups:
- Willingness of patients to collect blood, saliva and stool and consent to the preservation of all samples for study purposes.
- Age ≥ 18 years
- sufficient cognitive ability of the patients to understand the purpose of the study and to understand the purpose of the study and agree to it
Exclusion Criteria:
- Distant metastasis at the time of diagnosis and simultaneous second cancers, i.e. at study inclusion
- Malignancy in the last 5 years regardless of location (except basal cell carcinoma or cis of the uterine cervix)
- Carcinomas for which specimen collection is not possible or likely without compromising the compromise the pathological evaluation
- Persistent drug or medication abuse
- Patients who are unable or unwilling to comply with protocol and to be treated
- Patients who are represented by a legal guardian
- Patients who are not suitable for participation in the study due to a language barrier
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational Arm
Initial diagnosis of primary salivary gland carcinoma in the head and neck region
|
Evaluation of immune characteristics by using patient's stool, saliva and blood samples.
|
Control Group 1
Initial diagnosis of a benign salivary gland tumor in the head and neck region
|
Evaluation of immune characteristics by using patient's stool, saliva and blood samples.
|
Control Group 2
Healthy control group.
Functional diseases of the nose or ear (patients with the indication for functional ear surgery and rhinoplasty) without salivary gland tumor.
|
Evaluation of immune characteristics by using patient's stool, saliva and blood samples.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Observation of changes in an established immune matrix (intratumoral and systemic)
Time Frame: Change of the immune matrix from baseline to the end of study period, up to 5 years
|
Different immune cells and tumor cell markers will characterize immunological groups using cluster analysis.
Immune matrix of patients assessed by liquid immune profile-based signature (LIPS) (acc.
Zhou et al.
Journal for ImmunoTherapy of Cancer (JITC), 2021) and Tumour Associated Lymphocytes (TAL).
|
Change of the immune matrix from baseline to the end of study period, up to 5 years
|
Longitudinal immunophenotyping of the patients: Detection of about 30 distinct immune cell (sub)types together with their activation markers during study period
Time Frame: Change of the immunophenotyping from baseline to the end of study period, up to 5 years
|
The distribution of immune cells and messenger substances in the blood will be examined by means of immunophenotyping in order to add the systemic immune cell composition. Flow cytometric assessment of the amount of circulating immune cell-distribution per milliliter whole blood according to the LIPS technique (Zhou et al. JITC 2021). |
Change of the immunophenotyping from baseline to the end of study period, up to 5 years
|
Analysis of cytokines in peripheral blood and their change at certain points in the course of treatment
Time Frame: Change of the cytokine expression from baseline to the end of study period, up to 5 years
|
Electrochemiluminescent MULTI-ARRAY measurement of concentration (pg/ml whole blood) cytokines/chemoattractant cytokines in the serum/plasma of the patients according to the LIPS technique (Zhou et al.
JITC 2021).
|
Change of the cytokine expression from baseline to the end of study period, up to 5 years
|
Analysis of patient's metabolic state
Time Frame: The analyses are conducted from baseline to the end of study period, up to 5 years
|
Mass-spectrometric untargeted metabolomic of patients serum/plasma to assess the change of metabolites (pg/ml whole blood) from baseline to end of radiotherapy.
|
The analyses are conducted from baseline to the end of study period, up to 5 years
|
Analysis of patient's microbiomic state by examination of saliva, tumor and stool
Time Frame: The analyses are conducted from baseline to the end of study period, up to 5 years
|
16S rRNA deep sequencing of microbiome in salvia, tumour and stool samples to assess the presence and relative distribution of microbiotes (Operational taxonomic units (OTUs)).
|
The analyses are conducted from baseline to the end of study period, up to 5 years
|
Collaborators and Investigators
Investigators
- Study Director: Sarina Mueller, PD, Universitätsklinikum Erlangen, HNO
- Study Director: Marlen Haderlein, PD, Universitätsklinikum Erlangen, Radiation Oncology
- Principal Investigator: Benjamin Frey, PD, Universitätsklinikum Erlangen, Radiation Oncology, Translational Radiobiology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ImmoGlandula
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Salivary Gland Tumor
-
National Cancer Institute (NCI)TerminatedRecurrent Salivary Gland Cancer | Stage IVA Salivary Gland Cancer | Stage IVB Salivary Gland Cancer | Stage IVC Salivary Gland Cancer | High-grade Salivary Gland Mucoepidermoid Carcinoma | Salivary Gland Acinic Cell Tumor | Salivary Gland Adenocarcinoma | Salivary Gland Poorly Differentiated CarcinomaUnited States
-
Nantes University HospitalCompletedNon Tumor Salivary Gland Diseases of the Parotid Glands | Non Tumor Salivary Gland Diseases of the Submandibular Glands
-
Abramson Cancer Center at Penn MedicineMcCabe FundRecruiting
-
National Cancer Institute (NCI)CompletedRecurrent Salivary Gland Cancer | Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | High-grade Salivary Gland Carcinoma | High-grade Salivary Gland Mucoepidermoid Carcinoma | Low-grade Salivary Gland Carcinoma | Low-grade Salivary Gland Mucoepidermoid Carcinoma | Salivary Gland Acinic Cell... and other conditionsCanada
-
Aristotle University Of ThessalonikiCompletedDiagnosis | Salivary Gland TumorGreece
-
National Cancer Centre, SingaporeActive, not recruitingSalivary Gland Tumor | Rare Malignant NeoplasmSingapore
-
University of PittsburghAmgenWithdrawnAdenoma, Pleomorphic | Mixed Salivary Gland Tumor | Salivary Gland Tumor, Mixed | Syringoma, ChondroidUnited States
-
Western Galilee Hospital-NahariyaCompletedSalivary Gland TumorIsrael
-
Stanford UniversityCompletedSubmandibular Gland Tumor | Parotid Gland TumorUnited States
-
Assiut UniversityRecruiting
Clinical Trials on Sampling
-
Centre Hospitalier Sud FrancilienNot yet recruitingBacteria in Breast MilkFrance
-
Centre Hospitalier Universitaire DijonNot yet recruitingRhegmatogenous Retinal DetachmentsFrance
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
Institut PasteurInstitut National de la Santé Et de la Recherche Médicale, France; University... and other collaboratorsUnknownEncephalitisVietnam, Cambodia, Lao People's Democratic Republic, Myanmar
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Rennes University HospitalCompletedMultiple SclerosisFrance
-
Institut PasteurSanofi Pasteur, a Sanofi Company; Institut Pasteur of Cote d'IvoireCompletedBordetella Pertussis, Whooping CoughCôte D'Ivoire
-
University Hospital, ToulouseCompletedPneumonia, PneumocystisFrance
-
Institut CurieRecruitingProstate Cancer | Healthy DonorsFrance
-
Centre Hospitalier Universitaire de NīmesTechnological Innovations for Detection and Diagnosis LaboratoryCompleted